Skip to content

Accelerating Discoveries with Scailyte's Speed Strength

Accelerating Discoveries with Scailyte's Speed Strength

Accelerating Discoveries with Scailyte’s Speed Strength

Accelerating Discoveries with Scailyte's Speed Strength

In the world of clinical research and development, time is of the essence. Our mission at Scailyte is not just to innovate, but to revolutionize the way we approach discovery. Today, we’re shedding light on our Speed Strength – an edge that transforms the landscape of clinical R&D.

Numbers that Matter: We’re not just about impressive features; we back them up with hard-hitting numbers. Let’s talk about speed! Diana Stoycheva breaks it down: In a conventional single-cell analysis approach, unravelling differences between sample groups can take months. But with ScaiVision, our AI-driven powerhouse, it takes just a month to process data, unveil insights, and identify actionable differences – without the need for extensive clustering and annotation.

From Months to Moments: Picture this – the time you’d usually spend deciphering clusters and annotations, ScaiVision has already deciphered the crucial differences in your data. That’s 6x faster decision-making power. It’s not just efficiency; it’s about swiftly steering your clinical program in the right direction.

Discover, Design, Decide: ScaiVision isn’t just about speed; it’s about informed acceleration. By rapidly identifying actionable insights, it empowers you to make game-changing Go/No Go decisions. This means smarter, quicker, and more informed moves in your clinical journey.

Redesigning Clinical R&D: Our Speed Strength isn’t just about finding differences; it’s about shaping predictive biomarker assays for key clinical outcomes. While conventional methods struggle to keep up, ScaiVision empowers you to make data-driven choices that truly matter for your clinical trials.

De-risking the Future: In the dynamic realm of clinical R&D, speed doesn’t just mean efficiency – it translates to de-risking. With ScaiVision’s speed to discovery, we’re transforming challenges into opportunities, risks into rewards.

At Scailyte, we don’t just keep pace; we set the pace. Our Speed Strength isn’t just a feature; it’s a commitment to propelling you towards success, faster and smarter.

About Scailyte

Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets. 

Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.

For more information, visit www.scailyte.com and connect on social media @LinkedIn and @Twitter.

ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG.

Recent News

Scailyte at BIO International Convention 2024

We are thrilled to attend the Bio International Convention 2024 in San Diego on June 3-6 where busin...

Read more

Recent News

Inside Scailyte - Episode 10: Meet Dennis Göhlsdorf

In our latest episode of "Inside Scailyte," we're excited to introduce you to Dennis Göhlsdorf, our...

Read more

Recent News

Precision Med TRI-CON 2024

Join us for our presentation on "Enabling Precision Medicine by Combining Single-Cell Multi-Omics Da...

Read more

Recent News

Inside Scailyte - Episode 9: Meet Shaoline Sheppard

In the latest episode of "Inside Scailyte," we're thrilled to introduce you to Shaoline Sheppard, ou...

Read more

Recent News

NextGen Omics US 2024

Scailyte is headed to NextGen Omics US 2024 in Boston, MA on March 21-22. Join us as we showcase our...

Read more

Recent News

AI-driven single-cell data analysis identifies a cell signature predictive of neurotoxicity and clinical response in CAR-T cell therapy of DLBCL

In our latest white paper, "AI-driven single-cell data analysis identifies a cell signature predicti...

Read more

Recent News

Inside Scailyte - Episode 8: Meet Sajid Maqbool

Meet Sajid Maqbool, our Information Technology Engineer at Scailyte AG. In our latest episode of "In...

Read more

Recent News

Inside Scailyte – Episode 7: Meet Anna Dimitrova

Meet Anna Dimitrova, our Chief Financial Officer at Scailyte AG. In our latest episode of "Inside Sc...

Read more

Recent News

01 /04

Scailyte at BIO International Convention 2024

We are thrilled to attend the Bio International Convention 2024 in San Diego on June 3-6 where busin...

Read more

Inside Scailyte - Episode 10: Meet Dennis Göhlsdorf

In our latest episode of "Inside Scailyte," we're excited to introduce you to Dennis Göhlsdorf, our...

Read more

Recent News

02 /04

Precision Med TRI-CON 2024

Join us for our presentation on "Enabling Precision Medicine by Combining Single-Cell Multi-Omics Da...

Read more

Inside Scailyte - Episode 9: Meet Shaoline Sheppard

In the latest episode of "Inside Scailyte," we're thrilled to introduce you to Shaoline Sheppard, ou...

Read more

Recent News

03 /04

NextGen Omics US 2024

Scailyte is headed to NextGen Omics US 2024 in Boston, MA on March 21-22. Join us as we showcase our...

Read more

AI-driven single-cell data analysis identifies a cell signature predictive of neurotoxicity and clinical response in CAR-T cell therapy of DLBCL

In our latest white paper, "AI-driven single-cell data analysis identifies a cell signature predicti...

Read more

Recent News

04 /04

Inside Scailyte - Episode 8: Meet Sajid Maqbool

Meet Sajid Maqbool, our Information Technology Engineer at Scailyte AG. In our latest episode of "In...

Read more

Inside Scailyte – Episode 7: Meet Anna Dimitrova

Meet Anna Dimitrova, our Chief Financial Officer at Scailyte AG. In our latest episode of "Inside Sc...

Read more

Recent News